Dynavax Technologies | DVAX - Current Assets



Dynavax Technologies reported $785.71M in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
AbbVie USD 27.68B 2.09B Mar/2025
Adma Biologics USD 399.56M 68.15M Jun/2025
Amgen USD 26.73B 195M Jun/2025
AstraZeneca USD 28.94B 2.8B Jun/2025
Biogen USD 7.97B 341.7M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Bristol-Myers Squibb USD 33.22B 2.44B Jun/2025
Dynavax Technologies USD 785.71M 30.26M Jun/2025
Gilead Sciences USD 14.72B 2.18B Jun/2025
Glaxosmithkline GBP 17.67B 676M Jun/2025
Merck USD 37.07B 1.56B Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Novartis USD 25.94B 831M Jun/2025
Pfizer USD 43.7B 2.16B Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Roche Holding CHF 40.04B 6.41B Dec/2024
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
TG Therapeutics USD 663.96M 19.45M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025